Vir Biotechnology CFO Jason O’Byrne Resigns; Interim CFO Appointed

What Happened
Vir Biotechnology, Inc. (VIR) filed an 8-K (Item 5.02) reporting that Executive Vice President and Chief Financial Officer Jason O’Byrne, MBA, informed the company on July 20, 2026 that he will step down effective August 3, 2026 to pursue another opportunity. The filing states his resignation was not due to any disagreement with Vir Bio. On July 23, 2026, the Board appointed Brent Sabatini, CPA, MBA, Senior Vice President and Chief Accounting Officer, as interim “principal financial officer,” also effective August 3, 2026.

Key Details

• Effective date of change: August 3, 2026.
• Departing officer: Jason O’Byrne, MBA — stepping down to pursue another opportunity; no disagreement with the company reported.
• Interim appointee: Brent Sabatini, CPA, MBA (age 52) — Senior VP & Chief Accounting Officer since Feb 2023; principal accounting officer since Oct 2024.
• Compensation/relationships: No additional compensation or pay adjustment for Sabatini in connection with the interim role; no related-party transactions or family relationships disclosed. Company has begun a search for a permanent successor.

Why It Matters
A CFO transition is a material change in senior financial leadership. Investors should note the immediate appointment of an experienced interim financial officer with accounting and finance leadership experience (including roles at Amgen and Capsida) and that the company says the departure was not due to any disagreement. The company’s ongoing search for a permanent CFO and continuity in financial reporting roles (no compensation changes and an internal interim appointment) are relevant for assessing near-term financial oversight and reporting stability.